Early Detection of Chemotherapy-Related Left Ventricular Dysfunction
Early Detection of Chemotherapy-Related Left Ventricular Dysfunction
复制标题
DOI：
10.1007/s11886-012-0256-z
复制
发表时间：
2012-06-01
影响因子：
3.7
通讯作者：
DeCara, Jeanne M.
中科院分区：
文献类型：
--
作者：
DeCara, Jeanne M.
癌症治疗的现代进步提高了生存率。因此，癌症治疗对其他器官系统（如心脏）的影响更可能与临床相关。其中一种可能性是化疗相关的左心室功能障碍。虽然在临床实践中，心脏毒性是通过症状和左心室射血分数来评估的，但这些症状和射血分数发生在心脏代偿机制已经消耗之后的疾病过程中相对较晚的时间。理想情况下，左心室功能障碍将被及早发现，以便癌症患者及其医生能够就其治疗方案做出明智的决定，并在适当的情况下进行仔细的监测和早期开始心脏保护药物治疗。这篇综述讨论了超声心动图检测亚临床左心室功能障碍的癌症患者暴露于化疗与潜在的心脏毒性，特别是蒽环类药物和曲妥珠单抗。
Modern advances in cancer treatment have resulted in improved survival. As a result, effects of cancer therapy on other organ systems such as the heart are more likely to become clinically relevant. One such possibility is chemotherapy-related left ventricular dysfunction. Although in clinical practice cardiotoxicity is evaluated by symptoms and left ventricular ejection fraction, these occur relatively late in the disease process after the heart's compensatory mechanisms have been expended. Ideally, left ventricular dysfunction would be identified early so that cancer patients and their physicians can make informed decisions about their therapeutic options and institute careful surveillance and early initiation of cardioprotective medication where appropriate. This review discusses the role of echocardiography to detect subclinical left ventricular dysfunction in cancer patients exposed to chemotherapy with potential cardiotoxicity, particularly anthracyclines and trastuzumab.